Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has announced its plans to release second quarter 2024 financial results on August 14, 2024. The company will disclose its financial performance and provide a business update after the U.S. financial markets close on that day. Additionally, Arcutis will host a conference call and webcast at 4:30 p.m. ET to discuss the results. Investors and interested parties can access the live webcast and presentation materials through the 'Events' section of the company's website. An archived version of the webcast will be made available on the Arcutis investor website following the conference call.
Arcutis Biotherapeutics (Nasdaq: ARQT), un'azienda biofarmaceutica in fase commerciale specializzata in innovazioni nel campo dell'immuno-dermatologia, ha annunciato i suoi piani per pubblicare i risultati finanziari del secondo trimestre 2024 il 14 agosto 2024. L'azienda rilascerà le sue prestazioni finanziarie e fornirà un aggiornamento aziendale dopo la chiusura dei mercati finanziari statunitensi quel giorno. Inoltre, Arcutis ospiterà una teleconferenza e una diretta web alle 16:30 ET per discutere i risultati. Gli investitori e le parti interessate possono accedere alla diretta web e ai materiali di presentazione attraverso la sezione 'Eventi' del sito web dell'azienda. Una versione archiviata della diretta web sarà disponibile sul sito per gli investitori di Arcutis dopo la teleconferenza.
Arcutis Biotherapeutics (Nasdaq: ARQT), una empresa biofarmacéutica en etapa comercial especializada en innovaciones en inmunodermatología, ha anunciado sus planes de publicar los resultados financieros del segundo trimestre de 2024 el 14 de agosto de 2024. La empresa dará a conocer su desempeño financiero y proporcionará una actualización comercial después del cierre de los mercados financieros en EE. UU. ese día. Además, Arcutis llevará a cabo una llamada de conferencia y transmisión en vivo a las 4:30 p.m. ET para discutir los resultados. Los inversores y partes interesadas pueden acceder a la transmisión en vivo y a los materiales de presentación a través de la sección 'Eventos' del sitio web de la empresa. Una versión archivada de la transmisión estará disponible en el sitio web de inversores de Arcutis tras la llamada de conferencia.
Arcutis Biotherapeutics (Nasdaq: ARQT)는 면역 피부과 혁신을 전문으로 하는 상업 단계의 생물 의약품 회사로, 2024년 2분기 재무 결과를 2024년 8월 14일에 발표할 계획이라고 발표했습니다. 이 회사는 그날 미국 금융 시장이 닫힌 후 재무 성과를 공개하고 사업 업데이트를 제공할 것입니다. 또한 Arcutis는 그 결과를 논의하기 위해 동부 표준시 오후 4:30에 컨퍼런스 콜 및 웹캐스트를 진행할 예정입니다. 투자자 및 관심 있는 측은 회사 웹사이트의 '이벤트' 섹션을 통해 실시간 웹캐스트 및 발표 자료에 접근할 수 있습니다. 웹캐스트의 보관된 버전은 회의 후 Arcutis 투자자 웹사이트에서 제공될 것입니다.
Arcutis Biotherapeutics (Nasdaq: ARQT), une entreprise biopharmaceutique en phase commerciale spécialisée dans les innovations en immunodermatologie, a annoncé ses projets de publier les résultats financiers du deuxième trimestre 2024 le 14 août 2024. L'entreprise dévoilera ses performances financières et fournira une mise à jour commerciale après la clôture des marchés financiers américains ce jour-là. De plus, Arcutis organisera une téléconférence et un webinaire à 16 h 30 ET pour discuter des résultats. Les investisseurs et les parties intéressées peuvent accéder au webinaire en direct et aux documents de présentation via la section 'Événements' du site web de l'entreprise. Une version archivée du webinaire sera disponible sur le site des investisseurs d'Arcutis après la téléconférence.
Arcutis Biotherapeutics (Nasdaq: ARQT), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf Innovationen in der Immunodermatologie spezialisiert hat, hat Pläne angekündigt, die Finanzergebnisse des zweiten Quartals 2024 am 14. August 2024 zu veröffentlichen. Das Unternehmen wird seine finanzielle Leistung bekannt geben und ein Geschäftsin Update nach der Schließung der US-Finanzmärkte an diesem Tag bereitstellen. Darüber hinaus wird Arcutis um 16:30 Uhr ET eine Telefonkonferenz und ein Webcast durchführen, um die Ergebnisse zu besprechen. Investoren und Interessierte können über den Bereich 'Veranstaltungen' auf der Unternehmenswebsite auf den Live-Webcast und die Präsentationsmaterialien zugreifen. Eine archivierte Version des Webcasts wird nach der Telefonkonferenz auf der Investorenseite von Arcutis verfügbar sein.
- None.
- None.
WESTLAKE VILLAGE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report second quarter 2024 financial results and provide a business update on Wednesday, August 14, 2024 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET.
A live webcast of the call and the presentation materials will be available on the “Events” section of the Company’s website. An archived replay of the webcast will be available on the Arcutis investor website following the conference call.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram and X.
Forward-Looking Statements
Arcutis cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, and the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 27, 2024, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Latha Vairavan, Vice President, Finance and Investor Relation
ir@arcutis.com
FAQ
When will Arcutis Biotherapeutics (ARQT) report its Q2 2024 financial results?
What time is the Arcutis Biotherapeutics (ARQT) Q2 2024 earnings call scheduled for?
Where can I access the webcast for Arcutis Biotherapeutics' (ARQT) Q2 2024 earnings call?
Will there be a replay available for Arcutis Biotherapeutics' (ARQT) Q2 2024 earnings call?
